Study
Intravenous DMT Shows Promise in Reducing Depression Symptoms
A single dose of intravenous DMT with therapy significantly reduced depression symptoms for up to 3 months in adults with moderate-to-severe depression.
Summary
In plain language
Researchers explored the effects of a single intravenous dose of DMT combined with therapy on adults with moderate-to-severe major depressive disorder (MDD). They found that participants receiving DMT experienced a significant reduction in depression symptoms, which lasted up to three months. The study involved 34 participants who were randomly assigned to receive either DMT or a placebo. Those given DMT showed a greater improvement in their depression scores compared to the placebo group. This research suggests that DMT, when used with therapeutic support, may offer a new treatment option for individuals with MDD who haven't responded well to traditional treatments.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study tested intravenous DMT, a psychedelic substance, to see if it could help reduce symptoms of major depressive disorder.
Researchers conducted a randomized, placebo-controlled trial involving 34 participants with moderate-to-severe depression, giving them either DMT or a placebo.
The results showed that those who received DMT experienced a greater reduction in depression symptoms compared to the placebo group, with effects lasting up to 3 months.
The study noted mild to moderate side effects like nausea and anxiety, but no serious adverse effects were reported.
While promising, seniors should discuss this potential treatment with their healthcare providers, as more research is needed to explore its long-term effects and overall safety.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Intravenous DMT Shows Promise in Reducing Depression Symptoms
Published September 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored September 16, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study scored highly due to its rigorous randomized controlled trial design, comprehensive reporting, and publication in a high-quality journal. However, the lack of external replication and relevance to the target population of seniors aged 55+ limited the overall score. The absence of conflicts of interest and industry involvement contributed positively to the conflicts score.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 6.7/10 | |
| Statistical methods | 10.0/10 | |
| Reporting completeness | 10.0/10 | |
| Conflicts & funding | 10.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 0.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
This phase IIa trial evaluated the efficacy and safety of intravenous DMT in adults with moderate-to-severe major depressive disorder. The study found significant reductions in depression symptoms compared to placebo, with effects sustained up to 3 months.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were checked.
Conditions This Research Covers
These condition pages help connect the paper back to the real-world health concerns it addresses.
Anxiety
Anxiety is a common emotional state characterized by feelings of worry, fear, or unease. It can manifest in various ways, including physical symptoms like rapid heartbeat, sweating, and difficulty breathing. While a certain amount of anxiety is normal, excessive or persistent anxiety can significantly impact a person's quality of life.
Depression
Depression, a common mental health condition, can affect people of all ages, including seniors. It's characterized by persistent feelings of sadness, hopelessness, and a loss of interest in activities. While it can significantly impact daily life, it's important to remember that depression is treatable.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Cognitive Behavioral Therapy (CBT)
Cognitive Behavioral Therapy (CBT) is a structured form of talk therapy that helps individuals recognize and change negative thought patterns and behaviors. It’s one of the most widely researched and effective treatments for anxiety, depression, and stress. For older adults, CBT can improve coping skills, mood, and confidence in managing life’s challenges.
Psilocybin
Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. It is being studied for its potential to aid in mental health conditions, such as depression and anxiety, offering a new perspective on treatment. Seniors may find it beneficial, especially those seeking alternatives when traditional therapies have not been effective.
MDMA
MDMA therapy is an emerging treatment primarily used for addressing post-traumatic stress disorder (PTSD). It involves the controlled use of MDMA, a synthetic drug, under professional supervision to help improve emotional and psychological well-being. This treatment is gaining attention for its potential to enhance emotional processing and reduce symptoms of PTSD.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.